Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints... see more

NDAQ:APHA - Post Discussion

Aphria Inc. > Calmdown Buddy
View:
Post by N00bInvesT0R on Sep 06, 2020 12:11pm

Calmdown Buddy

Don't let the emotions get the best of you, it's understandble that you are frustrated if you have a high average price per share and currently have a red Return On Investment but that's part of the game, key word investment.

Here are the price action reasons why I would want to keep Irwin Simon :

Let's compare with our competitors (US tickers) :

  1. March 2020 bottom  when the virus officialy affected the market witth 
  2. Friday September  4th 2020 close price

Canopy Growth (CGC)

  1.   March 2020 low : 9.00$
  2.  Friday September 4th 2020 close price : 16.21$

That's a +80% performance

Aurora Cannabis (ACB)
 

  1. March 2020 low : 5.30$
  2.  Friday September 4th 2020 close price : 8.51$
That's a +60.5% performance

Cronos Group (CRON)

  1. March 2020 low : 4.00$
  2.  Friday September 4th 2020 close price : 5.39$

That's a +35% performance

Aphria (APHA)

  1. March 2020 low :  1.95$
  2. Friday September 4th 2020 close price  : 4.59$
That's a +135% Performance

To make a recap so you don't have to scroll up and down

  • APHA : +135%
  • CGC: + 80%
  • ACB  : +60.5%
  • CRON : +35%

Here are the fundamentals analysis  reasons why I would want to keep Irwin Simon :

  1. 5 Quarters in a row Ebidta Positive
  2. 5 Quarters in a row Recreational market share growth
  3. Aphria is #1 in recreational market revenues which is a market bigger than medical
  4. Aphria is #1 in international  revenues with a strong presence in Europe CC Pharma
  5. Aphria One is EU GMP meaning we can use CC Pharma channel to distribute and make sure we keep selling products in case of oversupply market  conditions in Canada
  6. Aphria is #1 for revenues in Fiscal  2020

Now when it comes to his salary I suggest you read this old post of mine  :

https://stockhouse.com/companies/bullboard?symbol=t.apha&postid=31147656

Salary that is overall in shares  that he can't cash out anytime.  When his RSUS will vest during 2021 it would only be in his best interest that by then the price per share appreciated which means that I'm sure he's doing everything in his power to have that appreciation.

There is no other canadian MJ company  that can brag about the 6 points I gave in the fundamental analysis reasons.

Therefore, I can only come to the conclusion that since Irwin Simon joined  Aphria he clearly turned the ship around even if having  him as a CEO seems costly $$$. All his experience  doesn't come cheap and there's no one else to thank expect  Irwin's vision , leadership and management he brought at Aphria.

Eventually share price will follow all the improvements Aphria made since Irwin arrived. It's only a matter of time before we're cash flow positive, last quarter,  the assets impairments + inventory writedown  were the only reason we didn't post a positive earning per share and who knows a positive cash flow. We only burned 18M$ when you  compare cash on hands from Q3 2020 to  Q4 2020.

Anyways Calmdown11 and anyone else that is paniced, you should really do more due diligence and do what I like to call benchmarking (comparing the competitors). You can also just click on my profile and look at my prior posts except the ones where I do technical analysis on the chart.


Hopefully this will help everyone to calm down and encourage everyone to do some benchmarking,

  1. Reading the financials of Aphria and competitors
  2. Reading the Management Discussion & Analysis of Aphria and competitors
  3. Listen to Aphria Conference alll and competitors
It's the only reason why I'm still invested in Aphria even thou my Return on Investment is also  negative since my investment journey, key word investment.  If Aphria was not improving like it has been doing since  the past 5 quarters, I would of sold all my shares and moved on long time ago, the problem is not the company, the problem is my timing, my average price per share.

You can read this post also to see what I have started doing to reduce my average pricer per  share (https://stockhouse.com/companies/bullboard?symbol=t.apha&postid=31440855)

I will post my technical analysis of the chart  tomorrow since we broke a key support  unfortunately like promised.

See you tomorrow, enjoy and relax :)

Comment by Steve0123 on Sep 06, 2020 4:38pm
Another great post. Appreciate the time you have takin to break all down, for the unsure and negative posters. Hopefully this is well received and the board can in fact CALM DOWN.  Cheers
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities